TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

Journal of Clinical Investigation

Volumn 121, Issue 5, 2011, Pages 1969-1973

  Welford, Abigail F ^a   Biziato, Daniela ^b,c   Coffelt, Seth B ^a   Nucera, Silvia ^b,c   Fisher, Matthew ^a   Pucci, Ferdinando ^b,c   Di Serio, Clelia ^c,d   Naldini, Luigi ^b,c   De Palma, Michele ^b   Tozer, Gillian M ^a   Lewis, Claire E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d University Centre of Statistics in the Biomedical Sciences (CUSSB)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; COMBRETASTATIN A4 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HYPOXIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR BLEEDING; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL SEPARATION; CHEMOKINE CXCL12; FEMALE; FLOW CYTOMETRY; MACROPHAGES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NECROSIS; NEOPLASM TRANSPLANTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CXCR4; STILBENES;

EID: 79955517032     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44562     Document Type: Article

References (25)

1. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res. 1997;57(10):1829-1834. (Pubitemid 27209705)
2. Tozer GM, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999; 59(7):1626-1634. (Pubitemid 29160136)
3. Hill SA, Chaplin DJ, Lewis G, Tozer GM. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int J Cancer. 2002;102(1):70-74.
4. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ. Combretastatin A4 phosphate has tumour antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003;21(15):2831-2842. (Pubitemid 46621830)
5. Tozer GM, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61(17):6413-6422. (Pubitemid 32785286)
6. Lin EY, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238-11246. (Pubitemid 46009952)
7. Bingle L, Brown NJ, Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254-265. (Pubitemid 34189413)
8. De Palma M, Venneri MA, Galli R. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumour vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005;8(3):211-226. (Pubitemid 41317592)
9. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumour angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003;9(6):789-795. (Pubitemid 36749231)
10. Venneri MA, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109(12):5276-5285. (Pubitemid 46890548)
11. Coffelt SB, et al. Angiopoietin-2 Regulates Gene Expression in TIE2-Expressing Monocytes and Augments Their Inherent Proangiogenic Functions. Cancer Res. 2010;70(13):5270-5280.
12. Pucci F, et al. A distinguishing gene signature shared by tumor-infiltrating TIE2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood. 2009;114(4):901-914.
13. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
14. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010; 70(14):5679-5685.
15. Murata R, Overgard J, Horsman MR. Comparative effects of combretastatin a- 4 disodium phosphate and 5,6-dimethylxanethenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues Int J Radiat Biol. 2001;77(2):195-204.
16. Ceradini DJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10(8):858-864. (Pubitemid 39070860)
17. Shaked Y, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 2009;69(19):7524-7528.
18. Fantin A, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116(5):829-840.
19. Shaked Y, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313(5794):1785-1787. (Pubitemid 44454154)
20. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13(3):193-205. (Pubitemid 351318369)
21. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25(8):911-920. (Pubitemid 47236916)
22. Dudley AC, et al. Bone marrow is a reservoir for pro-angiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010;116(17):3367-3371.
23. Pahler JC, et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia. 2008;10(4):329-340.
24. Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell. 2009;16(3):183-194.
25. Parkins CS, Holder AJ, Hill SA, Chaplin DJ, Tozer GM. Determinants of anti-vascular action by combretastatin A-4-phosphate:role of nitric oxide. Br J Cancer. 2000;83(6):811-816.